The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Greve, Gabriele ^a,b   Schiffmann, Insa ^a,c   Pfeifer, Dietmar ^a   Pantic, Milena ^a   Schüler, Julia ^d   Lübbert, Michael ^a,e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d CHARLES RIVER LABORATORIES   (United States)

^e DKTK   (Germany)

Author keywords

Chromatin modification; Epigenetic therapy; Erlotinib; Histone acetylation; Histone methylation; Non small cell lung cancer; TKI

Indexed keywords

CHECKPOINT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; HISTONE H3; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; PANOBINOSTAT; PROTEIN KINASE B; PROTEIN P53; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE;

A549 CELL LINE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL ASSAY; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DRUG POTENTIATION; DRUG SENSITIZATION; EGFR GENE; EPITHELIUM CELL; FLOW CYTOMETRY; GENE MUTATION; HCC827 CELL LINE; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; HUMAN CELL; IC50; IMMUNOBLOTTING; MONOTHERAPY; NCI H460 CELL LINE; NON SMALL CELL LUNG CANCER; ONCOGENE; PHENOTYPE; PROTEIN ABUNDANCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; DNA MICROARRAY; DRUG EFFECTS; GENETICS; LUNG TUMOR; MUTATION; PROTO ONCOGENE; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; ERLOTINIB HYDROCHLORIDE; GENES, ERBB-1; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; LUNG NEOPLASMS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84959122182     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1967-5     Document Type: Article

References (36)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29.
2. Ries LAG, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer Survival and Incidence from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2003;8:541-52.
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. N Engl J Med. 2004;350:2129-39.
4. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med. 2009;361:947-57.
5. Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013;14:981-8.
6. Tellez CS, Grimes MJ, Picchi MA, Liu Y, March TH, Reed MD, et al. SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome. Int J Cancer. 2014;135:2223-31.
7. Keller K, Jung M. Histone Deacetylase (HDAC) Inhibitors in Recent Clinical Trials for Cancer Therapy. In: Lübbert M, Jones PA, editors. Epigenetic Therapy of Cancer. Berlin, Heidelberg: Springer Berlin Heidelberg; 2014. p. 227-55.
8. Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, Takai N, et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer. 2007;121:656-65.
9. Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, et al. Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2010;28:56-62.
10. Jones DR, Moskaluk CA, Gillenwater HH, Petroni GR, Burks SG, Philips J, et al. Phase I Trial of Induction Histone Deacetylase and Proteasome Inhibition Followed by Surgery in Non-small Cell Lung Cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2012;7:1683-90.
11. Derks S, van Engeland M. Epigenetic Disturbances in Colorectal Cancer. In: Lübbert M, Jones PA, editors. Epigenetic Therapy of Cancer. Berlin, Heidelberg: Springer Berlin Heidelberg; 2014. p. 283-98.
12. Brazelle W, Kreahling JM, Gemmer J, Ma Y, Cress WD, Haura E, et al. Histone Deacetylase Inhibitors Downregulate Checkpoint Kinase 1 Expression to Induce Cell Death in Non-Small Cell Lung Cancer Cells. PLoS One. 2010;5:e14335.
13. Gray JE, Haura E, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenck M, et al. A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors. Clin Cancer Res. 2014;20:1644-55.
14. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, et al. Restoring E-Cadherin Expression Increases Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Cell Lines. Cancer Res. 2006;66:944-50.
15. Gerber DE, Boothman DA, Fattah FJ, Dong Y, Zhu H, Skelton RA, et al. Phase 1 study ofromidepsin plus erlotinib in advanced non-small cell lung cancer. Lung Cancer. 2015. [Epub ahead of print].
16. Witta SE, Jotte RM, Konduri K, Neubauer MA, Spira AI, Ruxer RL, et al. Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy. J Clin Oncol. 2012;30:2248-55.
17. Huang P-H, Plass C, Chen C-S. Effects of Histone Deacetylase Inhibitors on Modulating H3K4 Methylation Marks - A Novel Cross-Talk Mechanism between Histone-Modifying Enzymes. Mol Cell Pharmacol. 2011;3:39-43.
18. Blagitko-Dorfs N, Jiang Y, Duque-Afonso J, Hiller J, Yalcin A, Greve G, et al. Epigenetic Priming of AML Blasts for All-trans Retinoic Acid-Induced Differentiation by the HDAC Class-I Selective Inhibitor Entinostat. PLoS One. 2013;8:e75258.
19. Virmani AK, Fong KM, Kodagoda D, McIntire D, Hung J, Tonk V, et al. Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer. 1998;21:308-19.
20. Lieber M, Smith B, Szakal A, Nelson-Rees W, Todaro G. A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells. Int J Cancer. 1976;17:62-70.
21. Gazdar AF, Carney DN, Russell EK, Sims HL, Baylin SB, Bunn PA, et al. Establishment of Continuous, Clonable Cultures of Small-Cell Carcinoma of the Lung Which Have Amine Precursor Uptake and Decarboxylation Cell Properties. Cancer Res. 1980;40:3502-7.
22. Greve G, Schiffmann I, Lübbert M. Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid. J Cancer Res Clin Oncol. 2015.
23. Sethi G, Ahn KS, Chaturvedi MM, Aggarwal BB. Epidermal growth factor (EGF) activates nuclear factor-ΚB through IΚBα kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IΚBα. Oncogene. 2007;26:7324-32.
24. Modrek B, Ge L, Pandita A, Lin E, Mohan S, Yue P, et al. Oncogenic Activating Mutations Are Associated with Local Copy Gain. Mol Cancer Res. 2009;7:1244-52.
25. Kubo T, Yamamoto H, Lockwood WW, Valencia I, Soh J, Peyton M, et al. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer J Int Cancer. 2009;124:1778-84.
26. Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, et al. Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer. Clin Cancer Res. 2010;16:5489-98.
27. Motoshima K, Nakamura Y, Sano K, Ikegami Y, Ikeda T, Mizoguchi K, et al. Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics. Cancer Chemother Pharmacol. 2013;72:1299-304.
28. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood. 2005;105:1768-76.
29. Gottifredi V, Karni-Schmidt O, Shieh S-Y, Prives C. p53 Down-Regulates CHK1 through p21 and the Retinoblastoma Protein. Mol Cell Biol. 2001;21:1066-76.
30. Luo J, Su F, Chen D, Shiloh A, Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature. 2000;408:377-81.
31. Ohira T, Gemmill RM, Ferguson K, Kusy S, Roche J, Brambilla E, et al. WNT7a induces E-cadherin in lung cancer cells. Proc Natl Acad Sci U S A. 2003;100:10429-34.
32. Nightingale KP, Gendreizig S, White DA, Bradbury C, Hollfelder F, Turner BM. Cross-talk between Histone Modifications in Response to Histone Deacetylase Inhibitors. J Biol Chem. 2007;282:4408-16.
33. Duque-Afonso J, Yalcin A, Berg T, Abdelkarim M, Heidenreich O, Lübbert M. The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO. Oncogene. 2011;30:3062-72.
34. Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, Zeng C, et al. Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non-Small Cell Lung Cancer Cell Lines. Mol Cancer Res. 2006;4:521-8.
35. Schneider BJ, Kalemkerian GP, Bradley D, Smith DC, Egorin MJ, Daignault S, et al. Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Invest New Drugs. 2012;30:249-57.
36. Politi K, Ayeni D, Lynch T. The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic. Cancer Cell. 2015;27:751-3.